颅内动脉瘤动物模型相关研究进展

摘要
图/表
参考文献(25)
相关文章 (3)

全文: PDF (655 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要颅内动脉瘤（IA）是由颅内动脉病理性、局限性扩张引起的瘤样突起，其一但破裂可引起蛛网膜下腔出血，造成严重后果。目前IA的发病机制仍未阐明，临床仅能对存在高破裂风险患者进行手术治疗，这也使得许多IA患者将无法采取任何治疗，并需要承担IA随时破裂的风险。因此阐明IA的病因机制，进而研制出针对该疾病病因机制的预防与治疗药物，是解决上述问题的关键。由于人体组织较难获取，IA动物模型便成为主要的研究途径。本文将从IA动物模型的构建方法、病理改变和药物治疗探索等方面的进展进行综述，以期为进一步深入研究提供参考。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李丽1* 吴学佳2* 付浩1 王志宏1 陈冬3 孙丽1▲ 张芳4▲

关键词 ：颅内动脉瘤, 动物模型, 病因机制, 药物治疗

Abstract：Intracranial aneurysm (IA) is a tumor like process caused by pathological and localized dilatation of intracranial arteries, once ruptured, it can result in subarachnoid hemorrhage and cause serious consequences. At present, the pathogenesis of IA has yet to be clarified, which result in that onlypatients with high risk of rupture can be treated. Many IA patients have to bear the risk of IA rupture at any time. Therefore, clarifying the mechanism of IA and developing preventive and therapeutic drugsis the key to solve the above problems. Because of the difficulty of obtaining human tissue, IA animal model has become the main research approach. This article will review the progress of IA animal model construction methods, pathological changes and drug treatment, in order to provide reference for further research.

Key words： Intracranial aneurysm Animal model Etiology mechanism Drug therapy

基金资助:天津市卫生局科技基金项目（2015KZ126）；天津市卫生和计划生育委员会中医中西医结合科研课题（2015155）。

通讯作者: ▲通讯作者

作者简介: *共同第一作者

引用本文:

李丽1* 吴学佳2* 付浩1 王志宏1 陈冬3 孙丽1▲ 张芳4▲. 颅内动脉瘤动物模型相关研究进展[J]. 中国医药导报, 2017, 14(33): 44-46.
LI Li1* WU Xuejia2* FU Hao1 WANG Zhihong1 CHEN Dong3 SUN Li1▲ ZHANG Fang4▲. Research progress of animal models of intracranial aneurysms. 中国医药导报, 2017, 14(33): 44-46.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2017/V14/I33/44

[1] Ravindra VM，de Havenon A，Gooldy TC，et al. Validation of the unruptured intracranial aneurysm treatment score：comparison with real-world cerebrovascular practice [J]. J Neurosurg，2017（10）：1-7.
[2] Czorlich P，Sauvigny T，Ricklefs F，et al. Impact of dexamethasone in patients with aneurysmal subarachnoid haemorrhage [J]. Eur J Neurol，2017，44（2）：1021-1029.
[3] Shimizu K，Imamura H，Mineharu Y，et al. Endovascular treatment of unruptured paraclinoid aneurysms：single-center experience with 400 cases and literature review [J]. AJNR Am J Neuroradiol，2016，37（4）：679-685.
[4] Raymond J，Venne D，Allas S，et al. Healing mechanisms in experimental aneurysms. I. Vascular smooth muscle cells and neointimaformation [J]. J Neuroradiol，1999，26（1）：7-20.
[5] 李浩，马勃，李志强，等.犬动脉瘤动物模型的血流动力学分析[J].天津医药，2015，（10）：1133-1136，1221.
[6] Hashimoto N，Handa H，Hazama F. Experimentally induced cerebral aneurysms in rats [J]. Surg Neurol，1978，10（1）：3-8.
[7] Hashimoto N，Handa H，Hazama F. Experimentally induced cerebral aneurysms in rats：part Ⅱ [J]. Surg Neurol，1979，11（3）：243-246.
[8] Eldawoody H，Shimizu H，Kimura N，et al. Simplified experimental cerebral aneurysm model in rats：comprehensive evaluation of induced aneurysms and arterial changes in the circle of Willis [J]. Brain Res，2009，1300：159-168.
[9] Morimoto M，Miyamoto S，Mizoguchi A，et al. Mouse model of cerebral aneurysm：experimental induction by renal hypertension and local hemodynamic changes [J]. Stroke，2002，33（7）：1911-1915.
[10] Sawyer DM，Pace LA，Pascale CL，et al. Lymphocytes influence intracranial aneurysm formation and rupture：role of extracellular matrix remodeling and phenotypic modulation of vascular smooth muscle cells [J]. J Neuroinflammation，2016，13（1）：185.
[11] Aoki T，Kataoka H，Ishibashi R，et al. Impact of monocyte chemoattractant protein-1 deficiency on cerebral aneurysm formation [J]. Stroke，2009，40（3）：942-951.
[12] Gao L，Hoi Y，Swartz DD，et al. Nascent aneurysm formation at the basilar terminus induced by hemodynamics [J]. Stroke，2008，39（7）：2085-2090.
[13] Hashimoto N，Kim C，Kikuchi H，et al. Experimental induction of cerebral aneurysms in monkeys [J]. J Neurosurg，1987，67（6）：903-905.
[14] Aoki T，Fr?觟sen J，Fukuda M，et al. Prostaglandin E2-EP2-NF-κB signaling in macrophages as a potential therapeutic target for intracranial aneurysms [J]. Sci Signal，2017， 10（2）：465-474.
[15] Albrekkan FM，Bachir S，Jumaa MA，et al. Is there a genetic correlation between multiple sclerosis and cerebral aneurysms？[J]. World Neurosurg，2016，95：624.e1-624.e4.
[16] Chyatte D，Bruno G，Desai S，et al. Inflammation and intracranial aneurysms [J]. Neurosurgery，1999，45（5）：1137-1146.
[17] 高冉，任梦，李瑶，等.腹主动脉瘤炎症机制的研究进展[J].生理科学进展，2016，47（2）：88-92.
[18] Tanaka T，Moriyama T，Kawamura Y，et al. Puerarin suppresses macrophage activation via antioxidant mechanisms in a CaPO4-induced mouse model of aneurysm [J]. J Nutr Sci Vitaminol （Tokyo），2016，62（6）：425-431.
[19] Fennell VS，Kalani MY，Atwal G，et al. Biology of saccular cerebral aneurysms：a review of current understanding and future directions [J]. Front Surg，2016，32（3）：43-51.
[20] Aoki T，Yamamoto K，Fukuda M，et al. Sustained expression of MCP-1 by low wall shear stress loading concomitant with turbulent flow on endothelial cells of intracranial aneurysm [J]. Acta Neuropathol Commun，2016，4（1）：48-59.
[21] Liaw N，Fox JM，Siddiqui AH，et al. Endothelial nitric oxide synthase and superoxide mediate hemodynamic initiation of intracranial aneurysms [J]. PLoS One，2014，9（7）：e101721.
[22] Aoki T，Nishimura M. Targeting chronic inflammation in cerebral aneurysms：focusing on NF-kappa B as a putative target of medical therapy [J]. Expert OpinTher Targets，2010，14（3）：265-273.
[23] Kimura N，Shimizu H，Eldawoody H，et al. Effect of olmesartan and pravastatin on experimental cerebral aneurysms in rats [J]. Brain Res，2010，1322：144-152.
[24] Aoki T，Kataoka H，Ishibashi R，et al. Pitavastatin suppresses formation and progression of cerebral aneurysms through inhibition of the nuclear factor kappa B pathway [J]. Neurosurgery，2009，64（2）：357-365.
[25] 张婷，闫海洋，陈孝储，等.辛伐他汀对颅内动脉瘤大鼠端粒长度、端粒酶反转录酶及端粒重复序列结合因子2基因表达的影响[J].广西医学，2017，39（8）：1195-1197， 1202.